Prosthetic Heart Valve Devices and Equipment Market Report 2026

The prosthetic heart valve devices and equipment market size has grown strongly in recent years. It will grow from $6.73 billion in 2025 to $7.17 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of valvular heart diseases, rising aging population, expansion of cardiac surgery programs, growing adoption of valve replacement procedures, improvements in cardiac imaging technologies.

The prosthetic heart valve devices and equipment market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing preference for minimally invasive cardiac interventions, rising demand for longer-lasting valve implants, expansion of transcatheter valve indications, growing investments in structural heart disease treatment, increasing innovation in biological valve materials. Major trends in the forecast period include increasing adoption of transcatheter heart valve procedures, rising demand for tissue-based heart valves, growing use of minimally invasive valve repair systems, expansion of advanced valve durability technologies, enhanced focus on patient-specific valve solutions.

The increasing prevalence of valvular heart disease has fueled the demand for transcatheter aortic valve replacement (TAVR) procedures, thereby driving the growth of the prosthetic heart valve devices and equipment market. TAVR is a minimally invasive surgical procedure used to treat aortic stenosis, a valvular heart disease that impairs the function of the heart's aortic valve. Aortic stenosis causes the aortic valve to harden, restricting proper blood flow, and TAVR replaces the malfunctioning valve with a transcatheter valve. For example, in May 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that heart disease caused 702,880 deaths in the United States in 2022, accounting for one in every five fatalities. As the incidence of valvular heart diseases continues to rise, the number of TAVR procedures is expected to grow, driving the demand for transcatheter valves and propelling the market forward.

Leading companies in the prosthetic heart valve devices and equipment market are focusing on the development of tricuspid valve replacement systems to meet the increasing demand for effective treatments for tricuspid valve disease, enhance patient outcomes, and minimize complications associated with conventional heart valve surgeries. Tricuspid valve replacement systems are medical devices designed to replace the tricuspid valve in the heart, which regulates blood flow between the right atrium and right ventricle. For example, in October 2023, Edwards Lifesciences, a US-based technology company, received CE Mark approval for the EVOQUE system, making it the first transcatheter valve replacement therapy globally approved for treating tricuspid regurgitation (TR). The EVOQUE valve features a self-expanding nitinol frame and tissue leaflets derived from bovine pericardial tissue. It is designed for delivery via a low-profile transfemoral 28-French system and will be available in three sizes.

In July 2024, Edwards Lifesciences, a US-based provider of structural heart devices and critical care monitoring technologies, acquired JenaValve Technology, Inc. and Endotronix, Inc. for $1.2 billion. Through this acquisition, Edwards aims to broaden its transcatheter valve portfolio to address aortic regurgitation and to incorporate heart failure management capabilities. JenaValve Technology, Inc. is a US-based company developing the Trilogy transcatheter heart valve system for aortic regurgitation, while Endotronix, Inc. is a US-based medical technology company that develops implantable pulmonary artery pressure sensors for patients with heart failure.

Major companies operating in the prosthetic heart valve devices and equipment market are Boston Scientific Corporation, Edwards Lifesciences, Medtronic plc, LivaNova plc, Abbott Laboratories, Jenavalve Technology Inc., Lepu Medical Technology, Cryolife Inc., Neovasc Inc., Braile Biomedica, Colibri Heart Valve, TTK Healthcare Ltd., Medical Technology Est., Micro Interventional Devices Inc., Well Health Technologies, On-X Life Technologies Inc., Meril Life Sciences Pvt. Ltd., Sorin Group, Commonwealth Edison Company, Cardiac Dimensions Inc., CardioSolutions Inc., Leman Cardiovascular, MitralSolutions Inc., Thubrikar Aortic Valve Inc., LifeNet Health Inc., Xeltis AG, Transcatheter Technologies GmbH, Venus Medtech (Hangzhou) Inc., MValve Technologies Ltd., MVRx Inc., NaviGate Cardiac Structures Inc., Pulmonx Corporation, Tendyne Holdings Inc., ValveXchange Inc., Vascutek Ltd., XpandOrtho Inc., Zhejiang A&F Medical Co. Ltd.

North America was the largest region in global prosthetic heart valve devices and equipment market in 2025. Western Europe was the second-largest region in prosthetic heart valve devices and equipment market. The regions covered in the prosthetic heart valve devices and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prosthetic heart valve devices and equipment market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs are influencing the prosthetic heart valve devices and equipment market by increasing costs of imported biomaterials, precision alloys, delivery systems, imaging-compatible components, and specialized manufacturing equipment. Cardiac hospitals and specialty heart centers in North America and Europe are most affected due to reliance on imported high-value valve systems, while Asia-Pacific faces cost pressures on export manufacturing. These tariffs are raising procedural costs and impacting procurement cycles. However, they are also encouraging regional production, local sourcing of biomaterials, and expansion of domestic heart valve manufacturing capabilities.

The prosthetic heart valve devices and equipment market research report is one of a series of new reports that provides prosthetic heart valve devices and equipment market statistics, including prosthetic heart valve devices and equipment industry global market size, regional shares, competitors with a prosthetic heart valve devices and equipment market share, detailed prosthetic heart valve devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the prosthetic heart valve devices and equipment industry. This prosthetic heart valve devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prosthetic heart valve devices and equipment are artificial valves implanted in the hearts of patients with valvular heart disease. These devices help regulate blood flow within the heart, enhancing circulation and overall heart performance. They are available in mechanical and biological forms, providing patients with options tailored to their specific medical requirements and conditions.

The primary types of prosthetic heart valve devices and equipment include transcatheter heart valves, tissue heart valves, and mechanical heart valves. Transcatheter aortic valve replacement is an invasive procedure used to replace a thickened aortic valve that does not open fully. Product types within this category encompass repair products, mitral valve repair devices, and tricuspid valve repair devices. The technologies employed in prosthetic heart valve devices and equipment involve biological valves and decellularized valves, which are utilized in various healthcare settings such as hospitals and ambulatory surgery centers.

The prosthetic heart valve devices and equipment market consist of sales of mechanical heart valves, transcatheter heart valves, and tissue heart valves that are used for heart patients. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.